Condition: Locally Advanced Rectal Cancer · Sponsor: Beijing Friendship Hospital
This is a phase II/III, multi-center, open-label, 3-arm, randomized controlled trial assessing the efficacy and safety of neoadjuvant long-course chemoradiation combined with Tislelizumab (PD-1 inhibitor) and subsequent TME surgery, by comparing assorted endpoints between two experiment groups (Experiment group 1: chemoradiation+concurrent PD-1 inhibitor; Experiment group 2: chemoradiation+sequential PD-1 inhibitor) with a control group (chemoradiation only).
This description comes directly from the study's public registry record.
Zhongtao Zhang, M.D. · +8613801060364 · zhangzht@ccmu.edu.cn
Always discuss trial participation with your own doctor first.
| Beijing Friendship Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Completed |
| Beijing Chaoyang Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Completed |
| Beijing Hospital | Beijing, Beijing Municipality, China | Completed |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Xuanwu Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Completed |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05245474